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Abstract
Objective: The aim of this study is to characterize the presence 
of exercise oscillatory ventilation (EOV) and to relate it with other 
cardiopulmonary exercise test (CET) responses and clinical variables. 
Methods: Forty-six male patients (age: 53.1±13.6 years old; 
left ventricular ejection fraction [LVEF]: 30±8%) with heart failure 
were recruited to perform a maximal CET and to correlate the CET 
responses with clinical variables. The EOV was obtained according to 
Leite et al. criteria and VE/VCO2 > 34 and peak VO2 < 14 ml/kg/min 
were used to assess patients’ severity.
Results: The EOV was observed in 16 of 24 patients who 
performed the CET, as well as VE/VCO2 > 34 and peak VO2 < 14 ml/
kg/min in 14 and 10 patients, respectively. There was no difference 
in clinical and CET variables of the patients who presented EOV 
in CET when compared to non-EOV patients. Also, there was no 
difference in CET and clinical variables when comparing patients 
who presented EOV and had a VE/VCO2 slope > 34 to patients who 
just had one of these responses either. 
Conclusion: The present study showed that there was an 
incidence of patients with EOV and lower peak VO2 and higher 
VE/VCO2 slope values, but they showed no difference on other 
prognostic variables. As well, there was no influence of the presence 
of EOV on other parameters of CET in this population, suggesting 
that this variable may be an independent marker of worst prognosis 
in HF patients.
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Abbreviations, acronyms & symbols
ACE
AT
BMI
BTPS
CET
CHF
CMDC
EOV
FEV1
FV
FVC
HR
 = Angiotensin-converting enzyme
 = Anaerobic threshold
 = Body mass index
 = Body temperature pressure standard
 = Cardiopulmonary exercise test
 = Chronic heart failure
 = Carbon monoxide diffusion capacity
 = Exercise oscillatory ventilation
  = Forced expiratory volume in 1 second
 = Flow-volume
 = Forced vital capacity
 = Heart rate
LVEF
NYHA
PETCO2
PETO2
RER
RR
SpO2
SVC
VCO2
VE
VO2
 = Left ventricular ejection fraction
 = New York Heart Association
 = End-tidal partial pressure of carbon dioxide
 = End-tidal partial pressure of oxygen
 = Respiratory exchange ratio
 = Respiratory rate
 = Blood oxygen saturation
 = Slow vital capacity
 = Carbon dioxide production
 = Ventilation production
 = Oxygen consumption
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pulmonary test)[12], exercise-induced asthma, unstable angina 
or significant cardiac arrhythmias, and myocardial infarction 
within the previous six months; also, none of the subjects were 
tobacco users, alcohol dependents, or users of addicting drugs. 
No patient had been submitted to cardiovascular rehabilitation. 
All subjects presented the same clinical management, optimized 
medications, and were clinically stable. The eligible participants 
signed a written informed consent and the study protocol was 
approved by the Ethics Committee of Institution (protocol 
238/06 and protocol 970.098).
Experimental Procedure
The research was performed in an air-conditioned laboratory, 
with temperature between 22ºC and 24ºC, and relative humidity 
between 50 and 60%, always in the same period of the day 
(between 8 am and 12 pm). In the day before the test, patients 
were warned to avoid the intake of stimulating drinks, not to 
perform physical activity, and to have light meals and at least 
8 hours of sleep. First, the volunteers were familiarized with the 
experimental set and involved researchers. Before the test begun, 
the patients were examined to verify if the recommendations 
were followed. Then, the systolic and diastolic arterial blood 
pressure and the peripheral oxygen saturation were measured, 
and it was performed auscultation.
Pulmonary Function
Pulmonary function tests, measuring slow vital capacity 
(SVC), FVC, FEV1, and FEV1/FVC ratio, were carried out using the 
CardiO2 System (Medical Graphics Corporation, St. Paul, MO, 
USA). For comparative purposes, reference values from Knudson 
et al.[13], expressed in body temperature pressure standard (BTPS) 
conditions, were used. Carbon monoxide diffusion capacity 
(CMDC) was assessed by simple respiration model and static 
volumes were assessed by whole-body plethysmography. 
Technical procedures and the acceptability and reproducibility 
criteria were defined according to norms recommended by the 
American Thoracic Society[14].
Ventilatory and Metabolic Variables During CET
Ventilatory and metabolic variables were obtained by a 
computer connected to an ergospirometric measurement system 
(CardiO2 System), using the Breeze Suite 6 software package. Tidal 
volume was obtained by a Pitot pneumotachometer connected 
to the CardiO2 System and attached to a facial mask – which was 
selected considering the volunteer’s face size and providing an 
adequate fit in order to avoid air leakage. The device presents in 
real time applied power values (W) and pedaling speed (rpm), 
as well as VO2, VCO2, minute ventilation (VE), heart rate (HR), and 
blood oxygen saturation (SpO2). Ventilatory equivalent values 
(VE/VO2 and VE/VCO2), respiratory exchange ratio (RER), end-tidal 
partial pressure of oxygen (PETO2) and carbon dioxide (PETCO2), 
flow-volume (FV), and respiratory rate (RR) were also calculated 
and registered. The power applied to the cycle ergometer during 
exercise protocols was controlled by the system through an 
interface with the bicycle.
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INTRODUCTION
Cardiovascular ischemic events are the leading cause of 
chronic heart failure (CHF), which is a syndrome that is generally 
characterized by the classic left ventricular systolic impairment 
with consequent muscular peripheral dysfunction[1] caused 
by not only the low cardiac output, but also by medications, 
oxidative stress, and chronic hypoxemia, among others[2]. An 
important outcome of this peripheral muscular dysfunction is 
the reduced functional capacity, negatively affecting the patients’ 
autonomy and consequently their quality of life[2].
Many parameters are known as independent markers of 
severity and predictors of morbidity and mortality in this group 
of patients. The maximal inspiratory pressure has been shown 
as an independent variable to quantify the survival rate of 
these patients[3] because it may reflect the inspiratory muscle 
weakness, usually witnessed in them. Furthermore, the handgrip 
strength has also been reported as an isolated parameter of CHF 
severity[4]. In this context, we may highlight the significance of 
the cardiopulmonary exercise test (CET). It is a useful tool that 
induce physiological responses in exercise conditions that might 
not appear at rest conditions.
From the parameters obtained in the CET, many of them have 
been described as negatively influenced by CHF progression. 
It is quite well known that patients with CHF present low 
functional status and exercise capacity, with reduced peak oxygen 
consumption (VO2)[5,6]. Another powerful CET variable that may 
reflect the severity of these patients and, more specifically, the 
pulmonary congestion is the ventilation production (VE)/ carbon 
dioxide production (VCO2) slope, which shows the ventilatory 
inefficiency, mainly in those who have values > 34, strongly 
characterizing pulmonary congestion[7,8]. Also, the presence of 
oscillatory ventilation in rest or during exercise is being considered 
as an important variable with prognostic value of CET[9,10]. Besides 
this importance, there is still no standardization for obtaining and 
interpreting exercise oscillatory ventilation (EOV)[11].
Therefore, the aim of the present study is to characterize the 
presence of EOV and to relate it with other clinical variables in 
patients with CHF.
METHODS
Study Design 
This is an observational and transversal study with 
convenience sample.
Patients
Forty-six men with CHF were recruited by clinical assessment. 
Inclusion criteria were previous history of stable symptomatic 
CHF due to left ventricular systolic dysfunction, documented 
for at least six months (left ventricular ejection fraction [LVEF]: 
< 45%), New York Heart Association (NYHA) class between II-
III, and clinical stability for at least three months. Patients were 
excluded from study if they had clinical and/or functional 
evidence of obstructive pulmonary disease (forced expiratory 
volume in 1 second [FEV1]/forced vital capacity [FVC] < 70% in 
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a normal distribution was observed, parametric statistical tests 
were used. For intergroup comparisons, the t-Student pared test 
was applied. Demographics, anthropometrics, and clinical data 
were presented as means with standard deviation.
RESULTS
Forty-six male patients were recruited; 22 patients were 
excluded and 24 were included in the present study (Figure 1).
Table 1 shows age and anthropometric and clinical 
characteristics of these patients, as well as their functional status 
and the CET variables with their prognostic thresholds. Body 
mass index (BMI) average showed that most of the patients were 
overweight and they were in NYHA functional class II and III. 
Among the 24 included patients, 16 presented EOV.
Data Analysis 
The following parameters were analyzed in CET variables:
First Ventilatory Threshold (At) Obtained
Visual analysis of VO2 and VCO2 correlation curves, VE/VO2, 
and PETO2 were graphically represented in moving mean values 
each eight respiratory cycles. Subsequently, three independent 
observers determined the anaerobic threshold (AT) under the 
following situations: 1) V-slope: breaking point from linearity in VO2 
and VCO2 correlation curves; 2) VE/VO2: nadir point of this ratio, 
ensuring that a systematic increase occurs from it; and 3) PETO2: 
nadir point of this variable, from which a systematic increase begins. 
The CET data were set from the beginning of the ventilatory and 
metabolic variables responses to power output increments till the 
end of the exercise. Analysis of each observer was performed in an 
independent manner, on a 15 inches monitor (SyncMaster 550V, 
Samsung) connected to the MedGraphics software. 
Exercise Oscillatory Ventilation (EOV)
The presence of periodic breathing was obtained by the 
analysis of ventilation data, and it was confirmed if there were 
three consecutive cycles with minimal average amplitude of 5 l 
in these data (peak value minus the average of two in-between 
consecutive nadirs), as suggested by Leite et al.[15].
VE/VCO2 slope
VE and VCO2 data were analyzed from the beginning of the 
exercise till peak. Data were input into spreadsheet software 
(Microsoft Excel) to calculate VE/VCO2 slope via least squares 
linear regression (y = mx + b, m = slope). 
VE/VCO2 > 34 and peak VO2 < 14 ml/kg/min were used to 
assess patients’ severity.
Statistical Analyses 
Statistical analyses were performed using the SigmaPlot 
version 11.0.0.007 (for Windows®) with level of significance set at 
0.05. Data were submitted to a normality test (Shapiro-Wilk). As 
Table 1. Anthropometrics, clinical and cardiopulmonary 
exercise test (CET) data of the patients included in the present 
study. 
Variables (n=24)
Age (years) 53.1±13.6
Height (cm) 169±7
Mass (kg) 76.27±12.83
BMI (kg/m2) 26.5±3.8
Functional status
NYHA II/III 9/15
CET
Peak VO2 (ml/min) 1135.0±325.8
Peak VO2 (ml/kg/min) 15.1±4.1
AT VO2 (l/min) 655.8±189.1
AT VO2 (ml/kg/min) 8.7±2.5
Peak PETCO2 29.7±7.8
VE/VCO2 40.1±15.7
EOV Yes/No 16/8
Prognostic values
VE/VCO2 > 34 (n/%) 14/46
PeakVO2 < 14 ml/kg/min (n/%) 10/25
Medications
Diuretics (n) 14
Digitalics (n) 9
Beta-blockers (n) 24
ACE-inhibitors (n) 15
Mean ± standard deviation. ACE=angiotensin-converting 
enzyme; AT=anaerobic threshold; BMI=body mass index; 
EOV=exercise oscillatory ventilation; NYHA=New York Heart 
Association; PETCO2=end-tidal partial pressure of carbon 
dioxide; VE/VCO2=ventilation/carbon dioxide production; 
VO2=oxygen consumption
EXCLUDED (n=22)
No echocardiography (n=5)
Refuse to participate (n=4)
Multifocal ventricular arrhythmias (n=2)
Recent hospitalization (n=2)
Cardiac rehabilitation Program insertion (n=2)
Demand pacemakers (n=1)
Unstable angina during CET (n=1) 
Smokers (n=1) 
Treatment abandonment (n=1) 
Death  (n=1)
Poor signal quality (n=2) 
CHF (n=46)
Included (n=24)
Fig. 1 – Flowchart of the present study. CHF = chronic heart failure; 
CET = cardiopulmonary exercise test.
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patients, as well as EOV and VE/VCO2 > 34 in 46% of them.
Anthropometric data of CHF patients showed that they 
were overweight and that 15 of the 24 evaluated patients were 
classified as NYHA functional class III. Furthermore, they had a poor 
exercise performance on CET, which can be seen by the value of 
peak VO2 (15.1 ml/kg/min), presenting low peak workload values. 
The literature shows that CHF patients exhibit a low peak VO2[16] 
as a marker of exercise intolerance caused by many factors of this 
disease as the low cardiac output, pulmonary congestion, and 
alterations of metabolism on peripheral and ventilatory muscle 
fibers that lead to a muscular dysfunction with impact on exercise 
tolerance. Peak VO2 is also a prognostic variable of CET[5,6].
Other CET variables showed similarities between our study 
and the literature, specifically when it comes to the coexisting 
presence of EOV and other bad prognostic variables, such as 
VE/VCO2 > 34 and peak VO2 < 14 ml/kg/min[17]. One study has 
showed that the presence of the combination EOV and VE/VCO2 
> 34 is particularly more alarming because of the risk for adverse 
Figure 2 shows the data obtained from patients with 
EOV (EOV+) and patients who did not present EOV (EOV-) on 
incremental CET with other parameters obtained from the CET, 
as well as their clinical variables and age. There was no difference 
between EOV+ and EOV- groups. 
Also, there was no difference on age, clinical variables and 
parameters of the CET data obtained from patients with EOV and 
VE/VCO2 slope > 34 when compared to patients with EOV or VE/
VCO2 slope > 34, as shown on Table 2. Such analysis was performed 
to verify if the patients who presented these two concomitant 
responses had a more severe status than those who didn’t.
DISCUSSION
The present study’s main findings are: (i) no difference between 
CET variables in patients with EOV and non-EOV; (ii) the absence 
of difference on functional variables between CHF patients with 
EOV and VE/VCO2 > 34 and those with EOV or VE/VCO2 > 34; iii) 
the presence of EOV and peak VO2 < 14 ml/kg/min in 25% of the 
Fig. 2 – Analysis of age, cardiopulmonary exercise test and clinical variables of exercise oscillatory ventilation (EOV+) population and non-EOV 
(EOV-) population. (A) Peak oxygen consumption (ml/kg/min). (B) Peak oxygen consumption (ml/min). (C) Oxygen consumption (ml/kg/min) 
at anaerobic threshold (AT). (D) Oxygen consumption at AT (ml/min). (E) VE/VCO2 slope. (F) Age. (G) Left ventricular ejection fraction (LVEF) (%). 
(H) New York Heart Association (NYHA) functional class.
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to lung circulation, and a pulmonary edema due to a high ventricle 
filling pressure even when these patients are clinically stable and 
on optimized drug therapy[20].
Studies that evaluated the prognostic power of EOV obtained 
by the analysis of ventilatory pattern of CHF patients when 
submitted to a CET suggest that this variable seems to be the most 
important in the CET, even with better prognostic values than VE/
VCO2 slope[21]. Additionally, the presence of EOV combined with 
higher values of VE/VCO2, mainly > 34, is even more alarming and 
powerful to predict adverse cardiac events on CHF population[18], 
characterizing that these two ventilatory variables reflect the worst 
control on ventilation and ventilatory inefficiency and may be 
translated into a better prognostic definition[20]. In the present study, 
the comparison between patients with EOV and VE/VCO2 > 34 and 
patients with only one of these showed no statistical difference on 
CET ventilatory variables, age, nor their clinical status, such as LVEF. 
It is already known that the presence of EOV is not altered by LVEF, 
since Guazzi et al.[22] showed no difference in incidence of EOV in 
CHF patients with normal or reduced LVEF. It suggests the power 
of EOV as an independent CET marker of worst prognostic because 
it represents the poor hemodynamic and ventilatory adjust to 
physical exercise and did not correlate with other ventilatory and 
metabolic CET variables with prognostic values.
Some studies focused on treatment of EOV and showed 
that the pathological pattern of ventilation in EOV population 
can be modulated and even disappear. Three studies evaluating 
pharmacological therapy with inodilator (malrinone)[23] and 
selective pulmonary vasodilator (sildenafil)[24] have shown some 
attenuation on EOV. In another study based on aerobic training, 
for three months, 71% of the patients with stable congestive heart 
failure showed a good EOV response[25]. These studies evaluated 
cardiac events[18]. Otherwise, our results do not agree with the 
literature when it comes to the worst response of CET variables 
on EOV population, described as lower peak VO2, higher VE/
VCO2 slope, and lower rest and peak PETCO2, when compared 
to non-EOV population[17]. Hypotheses for these findings are 
the heterogeneity of exercise protocols in the literature and 
the absence of a gold standard to verify the presence of EOV in 
patients with profile and clinical status similar to our subjects. In 
a meta-analysis about the assessment of EOV, Cornelis et al.[11] 
have suggested the use of Corrà et al.[19] criteria, although none 
of the criteria available appears to be superior. This criterion 
should be applied to a constant load protocol since the VE 
data may not vary more than 15% compared to the mean of 
rest VE data, which is a physiological response expected on the 
incremental exercise protocol. Also, the presence of EOV may be 
longer than 60% of the exercise time. For the results presented, 
we used Leite et al.[15] criteria because these are not so subjective 
since the presence of EOV is not calculated through time, but as 
a continuous variation of the VE data with an waxing and waning 
pattern, and it is not influenced by the time of its appearance, 
but by its amplitude. Finally, we believe that Leite et al.[15] criteria 
could be more appropriate to assess EOV during incremental 
exercise test.  
Even though the trigger mechanisms of EOV are not totally 
understood, the main hypotheses are circulatory delay, increased 
chemosensivity, increased ergoreflex signaling, and/or pulmonary 
congestion[17]. The reduced cardiac output leads to a delayed 
lung-chemoreceptor circulation (peripheral/central); this and the 
inefficient control of VE caused by increased chemosensitivity 
lead to an exaggerated response of the ventilation[20]. From the 
hemodynamic view, there is an uncoupling on the right ventricle 
Table 2. Analysis of cardiopulmonary exercise test (CET) parameters of patients with exercise oscillatory ventilation (EOV+) and VE/
VCO2 >34 or just one of these variables. 
EOV (+) and VE/VCO2 >34 EOV (+) or VE/VCO2 > 34 P value
LVEF (%) 31.5±4.5 30±6.5 0.51
Peak VO2 (ml/kg/min) 13.8±3.7 16.1±5.1 0.25
Peak VO2 (ml/min) 1075.7±373.5 1199.0±349.9 0.47
AT VO2 (ml/kg/min) 8.3±2.3 9.4±3.1 0.39
AT VO2 (ml/min) 648.1±205.7 704.1±222.9 0.57
Age (years) 55.2±13.3 52.1±14.8 0.64
NYHA 2.7±0.5 2.6±0.5 0.68
Peak PETO2 (mmHg) 109.1±4.3 104.9±7.4 0.13
Peak PETCO2 (mmHg) 26.±3.7 31.±10.3 0.34
Peak workload (W) 84.9±27.6 91.3±31.0 0.64
HR (bpm) 123.5±27.0 122.5±19.8 0.92
Mean ± standard deviation. P value < 0.05
AT=anaerobic threshold; HR=heart rate; LVEF=left ventricle ejection fraction; NYHA=New York Heart Association; PetCO2=end-tidal 
partial pressure of carbon dioxide; PETO2=end-tidal partial pressure of oxygen; VE/VCO2=ventilation/carbon dioxide production; 
VO2=oxygen consumption
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stable patients on optimized drug therapy, which suggests that 
maybe EOV does not respond to standard treatment for CHF, 
requiring other approaches than pharmacological interventions, 
such as physical exercise.
Based on the present study’s findings, it is important to 
encourage further studies about EOV in CHF and other patients 
for a better comprehension of the role of EOV, as well as to 
establish a gold standard pattern to verify the presence of this 
variable in different diseases and levels of severity. Finally, this 
knowledge improves therapeutic strategies. 
Limitations
The absence of gold standard in obtaining EOV must be 
considered, also some tool to evaluate peripheral muscular 
strength would give information that could help the 
interpretation of the findings. Results may not be extrapolated 
to more severe patients. Finally, this study was made with a 
convenience sample and more subjects should be recruited to 
consolidate our findings. 
CONCLUSION
The present study showed that there was an incidence of 
patients with EOV and lower peak VO2 and higher VE/VCO2 slope 
values, but there was no difference on other prognostic variables. 
In addition, no influence of the EOV presence on other parameters 
of CET in this population was observed, suggesting that this CET 
variable may be an independent marker of severity in CHF patients.
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